File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: RNA Interference Therapy for Chronic Hepatitis B Predicts the Importance of Addressing Viral Integration When Developing Novel Cure Strategies

TitleRNA Interference Therapy for Chronic Hepatitis B Predicts the Importance of Addressing Viral Integration When Developing Novel Cure Strategies
Authors
Keywordshepatitis B treatment
short interfering RNA
functional cure
HBsAg seroclearance
HBsAg reduction
Issue Date2021
PublisherMolecular Diversity Preservation International (MDPI) AG.. The Journal's web site is located at http://www.mdpi.com/journal/viruses
Citation
Viruses, 2021, v. 13 n. 4, p. article no. 581 How to Cite?
AbstractChronic hepatitis B infection remains a globally important cause of morbidity and mortality and has recently undergone a renaissance in therapeutic interest with increased pre-clinical and clinical testing of new drug classes. One of the first new classes in the clinic was RNA interference agents, which have the potential to impact the entire viral life cycle by reducing all virus-produced mRNA. Early clinical testing with the first of these agents in the clinic, ARC-520, demonstrated that rapid and deep reductions in viral proteins, RNA and DNA could be produced with this approach, but also the surprising insight that HBsAg production from incomplete HBV DNA integrated into the host genome appears to play a heretofore unappreciated and important role in maintaining circulating HBsAg, thought to play a fundamental role in preventing host clearance of the virus. Thus, accounting for viral DNA integration in novel HBV treatment approaches may prove to be essential to achieving successful finite therapies of this difficult to treat chronic infection.
Persistent Identifierhttp://hdl.handle.net/10722/304258
ISSN
2023 Impact Factor: 3.8
2023 SCImago Journal Rankings: 1.140
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorWooddell, CI-
dc.contributor.authorGehring, AJ-
dc.contributor.authorYuen, MF-
dc.contributor.authorGiven, BD-
dc.date.accessioned2021-09-23T08:57:28Z-
dc.date.available2021-09-23T08:57:28Z-
dc.date.issued2021-
dc.identifier.citationViruses, 2021, v. 13 n. 4, p. article no. 581-
dc.identifier.issn1999-4915-
dc.identifier.urihttp://hdl.handle.net/10722/304258-
dc.description.abstractChronic hepatitis B infection remains a globally important cause of morbidity and mortality and has recently undergone a renaissance in therapeutic interest with increased pre-clinical and clinical testing of new drug classes. One of the first new classes in the clinic was RNA interference agents, which have the potential to impact the entire viral life cycle by reducing all virus-produced mRNA. Early clinical testing with the first of these agents in the clinic, ARC-520, demonstrated that rapid and deep reductions in viral proteins, RNA and DNA could be produced with this approach, but also the surprising insight that HBsAg production from incomplete HBV DNA integrated into the host genome appears to play a heretofore unappreciated and important role in maintaining circulating HBsAg, thought to play a fundamental role in preventing host clearance of the virus. Thus, accounting for viral DNA integration in novel HBV treatment approaches may prove to be essential to achieving successful finite therapies of this difficult to treat chronic infection.-
dc.languageeng-
dc.publisherMolecular Diversity Preservation International (MDPI) AG.. The Journal's web site is located at http://www.mdpi.com/journal/viruses-
dc.relation.ispartofViruses-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjecthepatitis B treatment-
dc.subjectshort interfering RNA-
dc.subjectfunctional cure-
dc.subjectHBsAg seroclearance-
dc.subjectHBsAg reduction-
dc.titleRNA Interference Therapy for Chronic Hepatitis B Predicts the Importance of Addressing Viral Integration When Developing Novel Cure Strategies-
dc.typeArticle-
dc.identifier.emailYuen, MF: mfyuen@hku.hk-
dc.identifier.authorityYuen, MF=rp00479-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.3390/v13040581-
dc.identifier.pmid33808298-
dc.identifier.pmcidPMC8065501-
dc.identifier.scopuseid_2-s2.0-85103919919-
dc.identifier.hkuros325488-
dc.identifier.volume13-
dc.identifier.issue4-
dc.identifier.spagearticle no. 581-
dc.identifier.epagearticle no. 581-
dc.identifier.isiWOS:000643763300001-
dc.publisher.placeSwitzerland-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats